Multi-pole synchronous pulmonary artery radiofrequency ablation catheter
A multi-pole synchronous pulmonary artery radiofrequency ablation catheter may comprise a control handle, a catheter body and an annular ring. One end of the catheter body may be flexible, and the flexible end of the catheter body may be connected to the annular ring. The other end of the catheter body may be connected to the control handle. A shape memory wire may be arranged in the annular ring. One end of the shape memory wire may extend to an end of the annular ring and the other end of the shape memory wire may pass through a root of the annular ring and be fixed on the flexible end of the catheter body. The annular ring may be provided with an electrode group. The device can be used to treat pulmonary hypertension or heart failure with pulmonary denervation.
1. A method for treating a heart disease or appearance or worsening signs of heart failure, the method comprising:
i. positioning an ablation device in a pulmonary artery trunk of a patient, the pulmonary artery trunk including a distal portion of a main pulmonary artery, a proximal portion of a left pulmonary artery, and a proximal portion of a right pulmonary artery, and
ii. ablating a target tissue in the pulmonary artery trunk to affect an increase in one or more of 6-minute walk distance (6MWD) or cardiac output from at least 6 months after the ablating to 2 years after the ablating,
wherein the target tissue comprises at least one of the distal portion of the main pulmonary artery, the proximal portion of the left pulmonary artery, or the proximal portion of the right pulmonary artery; and
wherein ablating the target tissue comprises ablating one or more of a first ablation site at a left lateral apex of the distal portion of the main pulmonary artery, a second ablation site at an anterior side of the left lateral apex of the distal portion of the main pulmonary artery, or third ablation site at a posterior side of the left lateral apex of the distal portion of the main pulmonary artery.
2. The method of claim 1 , wherein the increase in one or more of 6-minute walk distance (6MWD) or cardiac output at least 6 months after the ablating is about 15%.
3. The method of claim 1 , wherein ablating the target tissue comprises applying at least one of radiofrequency (RF) energy, microwave energy, ultrasound energy, focused ultrasound energy, ionizing energy, electroporation, a drug, a chemical agent, or cryoablation to the target tissue.
4. The method of claim 1 , wherein positioning the ablation device comprises positioning an expandable ablation element of the ablation device adjacent the target tissue and wherein ablating the target tissue comprises ablating the target tissue with the ablation element positioned adjacent the target tissue, the ablation element comprising one or more ablation electrodes.
5. The method of claim 1 , wherein ablating the target tissue causes disruption of sympathetic nerves at the pulmonary artery trunk.
6. The method of claim 1 , wherein positioning the ablation device in the pulmonary artery trunk of the patient comprises advancing the ablation device into a femoral vein of the patient, upwardly into an inferior vena cava of the patient, then upwards into a right atrium of the patient, then down into a right ventricle of the patient, and then up through a pulmonary semilunar valve of the patient to the main pulmonary artery trunk.
7. A method for treating a heart disease or appearance or worsening signs of heart failure, the method comprising:
i. positioning an ablation device in a pulmonary artery trunk of a patient, the pulmonary artery trunk including a distal portion of a main pulmonary artery, a proximal portion of a left pulmonary artery, and a proximal portion of a right pulmonary artery, and
ii. ablating a target tissue in the pulmonary artery trunk to affect a reduction in mean pulmonary artery pressure and a reduction in systolic pulmonary artery pressure,
wherein the target tissue comprises at least one of the distal portion of the main pulmonary artery, the proximal portion of the left pulmonary artery, or the proximal portion of the right pulmonary artery.
8. The method of claim 7 , wherein the reduction in mean pulmonary artery pressure and a reduction in systolic pulmonary artery pressure is about 15%.
9. The method of claim 7 , wherein ablating the target tissue comprises applying at least one of radiofrequency (RF) energy, microwave energy, ultrasound energy, focused ultrasound energy, ionizing energy, electroporation, a drug, a chemical agent, or cryoablation to the target tissue.
10. The method of claim 7 , wherein positioning the ablation device comprises positioning an expandable ablation element of the ablation device adjacent the target tissue and wherein ablating the target tissue comprises ablating the target tissue with the ablation element positioned adjacent the target tissue, the ablation element comprising one or more ablation electrodes.
11. The method of claim 7 , wherein ablating the target tissue comprises ablating one or more of a first ablation site at a left lateral apex of the distal portion of the main pulmonary artery, a second ablation site at an anterior side of the left lateral apex of the distal portion of the main pulmonary artery, or third ablation site at a posterior side of the left lateral apex of the distal portion of the main pulmonary artery.
12. The method of claim 7 , wherein ablating the target tissue causes disruption of sympathetic nerves at the pulmonary artery trunk.
13. The method of claim 7 , wherein positioning the ablation device in the pulmonary artery trunk of the patient comprises advancing the ablation device into a femoral vein of the patient, upwardly into an inferior vena cava of the patient, then upwards into a right atrium of the patient, then down into a right ventricle of the patient, and then up through a pulmonary semilunar valve of the patient to the main pulmonary artery trunk.